Table 3.
Prognostic factor influencing overall survival
| Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| T stage (UICC Stage T4) | 0.861 (0.471–1.574) | 0.626 | ||
| Tumor size (maximum axial diameter > 10 cm) | 1.683 (1.060–2.671) | 0.027 | 1.393 (0.860–2.256) | 0.178 |
| AFP (>400 ng/ml) | 1.913 (1.171–3.126) | 0.010 | 1.402 (0.827–2.375) | 0.209 |
| PVTT site (main + 1st branch) | 1.271 (0.669–2.416) | 0.464 | ||
| PVTT size (maximum axial diameter > 3 cm) | 1.204 (0.671–2.160) | 0.534 | ||
| Tumor objective response (CR + PR) | 1.984 (1.210–3.254) | 0.007 | 2.090 (1.251–3.487) | 0.005 |
| PVTT objective response (CR + PR) | 1.580 (0.990–2.522) | 0.055 | ||
| PVTT complete response (CR) | 0.475 (0.227–0.994) | 0.048 | 0.445 (0.205–0.968) | 0.041 |
HR = hazard ratio; CI = confidence interval; AFP = alpha feptoprotein; PVTT = portal vein tumor thrombosis; CCRT = concurrent chemoradiotherapy; UICC = International Union Against Cancer; CR = complete response; PR = partial response.